Dublin, May 07, 2024 (GLOBE NEWSWIRE) -- The "Global Macular Degeneration Treatment Market Report by Type, Stage of Disease, Route of Administration, End User, and Region 2024-2032" report has been added to ResearchAndMarkets.com's offering.
The global macular degeneration treatment market has exhibited significant development with a market valuation of US$ 9.4 billion in 2023. Prospects for this sector indicate an anticipated enlargement to US$ 15.4 billion by 2032, advancing at a compound annual growth rate (CAGR) of 5.64% over the forecast period from 2023-2032. Given the enhancing focus on eye health and innovative treatment modalities, the market is set to confront a transformative phase in the coming years.
Primary market propulsion is attributed to the rising prevalence of age-associated macular degeneration and the increase in obesity rates worldwide. Modern dietary routines and sedentary lifestyles are augmenting the incidence of macular degeneration, while excessive screen exposure due to reliance on digital devices poses additional risks. Groundbreaking advancements, such as the development of retinal gene therapies, are injecting novel dynamism into the treatment paradigm.
In addition, the healthcare infrastructure's robust improvements coupled with intensive research and development initiatives for new drug formulations are significantly contributing to the market's growth trajectory. Government-led health initiatives are further reinforcing this expansion, underlining the sector's potential for widespread impact on public health.
Segmental Analysis and Regional Insights
The report segments the macular degeneration treatment market into various categories including type, stage of disease, route of administration, and end user, offering granular analysis for targeted interventions. Geographically, the research sheds light on regional market dynamics, focusing on territories such as North America, Asia-Pacific, Europe, Latin America, and the Middle East and Africa, thus providing a comprehensive perspective of the global landscape.
Competitive Landscape and Future Outlook
A focused view on the competitive scenario foregrounds prominent industry players that are innovating and shaping the market's future. Companies featured include:
- Aerie Pharmaceuticals Inc.
- Bausch Health Companies Inc.
- Bayer AG
- F. Hoffmann-La Roche Ltd.
- Iveric Bio Inc.
- Novartis AG
- Panoptica
- Pfizer Inc.
- Phio Pharmaceuticals
- Regeneron Pharmaceuticals Inc.
- Regenxbio Inc.
- Santen Pharmaceutical Co. Ltd.
Key Attributes
| Report Attribute | Details |
| No. of Pages | 137 |
| Forecast Period | 2023-2032 |
| Estimated Market Value (USD) in 2023 | $9.4 Billion |
| Forecasted Market Value (USD) by 2032 | $15.4 Billion |
| Compound Annual Growth Rate | 5.6% |
| Regions Covered | Global |
For more information about this report visit https://www.researchandmarkets.com/r/js9byc
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
